Little-known startup, backed by Foresite and Samsara, swings $60M China I&I deal

A new, still-in-stealth biotech is paying eight figures to acquire the rights to an experimental I&I drug out of China.

Vignette Bio — a company backed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Upstream Bio files for IPO in sign of life for biotech public offerings

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 19, 2024

Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes – Biotech Investments

EQS-News: Formycon AG / Key word(s): 9 Month figures/Quarterly / Interim Statement Formycon reports nine-month results for 2024 and continues growth trajectory with further operational

November 29, 2024

Third antigen’s a charm: Gilead pens deal with Merus for up to three trispecific antibodies

Gilead has enlisted Merus in a research deal to develop new trispecific antibodies that can harness the immune system to fight cancer. Merus will receive

March 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.